Skip to contentT
Travere Therapeutics, Inc.
T
TVTXTravere Therapeutics, Inc. Q3 2020 · 10-Q
Revenue$51.14M$51.14M+15.2% vs Q3 2019 Net Income-$22.55M-$22.55MN/M vs Q3 2019 EPS Diluted-$0.44-$0.44N/M vs Q3 2019 Operating Income-$19,435,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Travere Therapeutics, Inc. · CIK 1438533 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$4,327,000N/M Margins · derivedOperating margin-38.0%+39.6 pt vs Q3 2019
Net margin-44.1%+38.1 pt vs Q3 2019
ended Sep 30, 2020 · filed Nov 5, 2020 · 36 d after period end